免疫细胞有效剂量对食管癌放化疗后淋巴细胞减少及生存的影响
本研究纳入488例接受同步放化疗(联合或不联合手术)的食管癌患者,分析免疫细胞有效剂量(EDIC)与放射性淋巴细胞减少及临床结局的关系。结果显示EDIC中位值为3.6 Gy,EDIC>4.0 Gy者4级淋巴细胞减少比例显著更高(67.3% vs 40.8%,P<0.001),且EDIC升高与更差的OS、PFS和DMFS独立相关。
要点
- EDIC>4.0 Gy者4级淋巴细胞减少发生率显著高于EDIC≤4.0 Gy者(67.3% vs 40.8%)。
- 4级淋巴细胞减少与更差的OS、PFS和DMFS相关。
- 多因素分析显示EDIC升高是OS、PFS和DMFS更差的独立负相关因素。
核心结论
- EDIC可作为预测食管癌同步放化疗后淋巴细胞减少和不良临床结局的实用工具,建议将其控制在4 Gy以下。
研究设计与样本
- 回顾性分析488例接受同步放化疗(联合或不联合手术)的食管癌患者,采用Cox模型分析EDIC与生存结局的相关性。
主要发现
- 4级淋巴细胞减少导致OS、PFS和DMFS更差。
- EDIC中位值为3.6 Gy(范围0.8-6.0 Gy),EDIC越高与严重淋巴细胞减少强相关,尤其当EDIC超过4 Gy时。
- EDIC>4.0 Gy组4级淋巴细胞减少比例为67.3%,EDIC≤4.0 Gy组为40.8%(P<0.001)。
- 多因素分析中,EDIC升高与更差的OS、PFS和DMFS独立且负向相关。
关键数值与推荐
- EDIC计算模型:EDIC=0.12×MLD+0.08×MHD+0.15×0.85×MlD×n451/2+0.45+0.35×0.85×nk1/2×ITD62×103,其中n为分次数。
- 淋巴细胞减少按CTCAE 4.0版分级。
- 建议将EDIC控制在4 Gy以下。
临床怎么用
- 在食管癌同步放化疗计划设计中应计算EDIC,并尽量将其控制在4 Gy以下以减少严重淋巴细胞减少。
- 对EDIC>4.0 Gy的患者应警惕4级淋巴细胞减少及不良生存结局的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To test the hypothesis that effective dose to circulating immune cells (EDIC) impacts the severity of radiation-induced lymphopenia and clinical outcomes of esophageal cancer patients treated with concurrent chemoradiotherapy (CCRT). MATERIAL AND METHODS: 488 esophageal cancer patients treated with CCRT with and without surgery were analyzed. The EDIC model considers the exposure of circulating immune cells as the proportion of blood flow to lung, heart, liver, and the volume of the exposed area of the body, with the basis of mean lung dose (MLD), mean heart dose (MHD), mean liver dose (MlD), and integral dose (ITD) of the body region scanned, calculated as: EDIC=0.12∗MLD+0.08∗MHD+0.15∗0.85∗MlD∗n451/2+0.45+0.35∗0.85∗nk1/2∗ITD62∗103 Where n is the fraction number. Correlations of EDIC with overall survival (OS), progression free survival (PFS), distant metastasis free survival (DMFS), and locoregional control (LRC) rates were analyzed using both univariable and multivariable Cox models. Lymphopenia during CCRT was graded according to Common Terminology Criteria for Adverse Events version 4.0. RESULTS: Grade 4 lymphopenia resulted in inferior clinical outcomes, including OS, PFS, and DMFS. The median EDIC was 3.6 Gy (range, 0.8-6.0 Gy). Higher EDIC was strongly associated with severe lymphopenia, particularly when EDIC was above 4 Gy. Patients with EDIC > 4.0 Gy had more G4 lymphopenia than those with EDIC ≤ 4.0 Gy (67.3% vs. 40.8%; P < 0.001). On multivariate analysis, increasing EDIC was independently and inversely associated with worse OS, PFS, and DMFS. CONCLUSION: EDIC can be recommended as a useful tool to predict lymphopenia and inferior clinical outcomes, and it should be minimized below 4 Gy.
引用
- Xu C, Jin JY, Zhang M, et al. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol. 2020. PMID: 32182504. doi:10.1016/j.radonc.2020.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。